BioTime to Participate in Upcoming Conferences
November 13 2017 - 7:00AM
Business Wire
BioTime, Inc. (NYSE American: BTX), a late stage clinical
biotechnology company focused on developing and commercializing
products addressing degenerative diseases, today announced that its
management will participate in the following conferences:
- Torrey Hills Capital Emerging Growth
Conference on Tuesday, November 14, 2017. This conference is being
held at the Morgan Run Club and Resort in Rancho Santa Fe, CA.
- LD Micro 10th Annual Main Event
Conference on Wednesday, December 6, 2017. This conference is being
held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
At each conference mentioned above the Company will be hosting
one-on-one and group meetings throughout the day. Analysts and
portfolio managers that wish to attend the conference or would like
to request a meeting should contact Torrey Hills Capital or LD
Micro.
About BioTime
BioTime is a late stage clinical biotechnology company focused
on developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting
three primary sectors, aesthetics, ophthalmology and cell and drug
delivery. Its clinical programs are based on two platform
technologies: pluripotent cells, which can become any type of cell
in the human body, and cell/drug delivery. Renevia®, a cell
delivery product, met its primary endpoint in an EU pivotal
clinical trial for the treatment of facial lipoatrophy in HIV
patients earlier this year. Submission for approval of Renevia® in
the EU is expected to be early 2018, with possible approval and
commercial launch in 2018. There were no device related serious
adverse events reported. OpRegen®, a retinal pigment epithelium
transplant therapy, is in a Phase I/IIa multicenter trial for the
treatment of dry age-related macular degeneration, the leading
cause of blindness in developing countries. There were no related
serious adverse events reported. BioTime also has significant
equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation
(NYSE American: OCX), and a private company, AgeX Therapeutics,
Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert list:
http://news.biotime.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171113005372/en/
Investor Contact:BioTimeDavid Nakasone,
510-871-4188Dnakasone@biotime.comMedia Contact:JQA Partners,
Inc.Jules Abraham, 917-885-7378jabraham@jqapartners.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024